Guidelines on "pharmacotherapy of neurodegenerative dementia". An update

被引:0
作者
Fassbender, K. [1 ]
Froelich, L. [2 ]
机构
[1] Univ Saarland, Neurol Klin, D-66424 Homburg, Germany
[2] Heidelberg Univ, Med Fak Mannheim, Abt Gerontopsychiat, Zentralinst Seel Gesundheit, Mannheim, Germany
来源
NERVENARZT | 2014年 / 85卷 / 12期
关键词
Pharmacotherapy; Dementia; Alzheimer's disease; Frontotemporal dementia; Lewy body dementia; ALZHEIMERS-DISEASE; DOUBLE-BLIND; LEWY BODIES; NEUROLEPTIC SENSITIVITY; FRONTOTEMPORAL DEMENTIA; MEMANTINE TREATMENT; CONTROLLED-TRIAL; DONEPEZIL; MODERATE; PREVALENCE;
D O I
10.1007/s00115-014-4189-1
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
This article presents the evidence-based pharmacotherapeutic options for the most common forms of neurodegenerative dementia. The aim is to present the recommendations derived from the relevant studies on the neurological, psychiatric and geriatric practice of treatment for dementia patients. The text is derived from the 2009 guidelines of the German Society of Neurology (DGN, lead management: K. Fassbinder), the S3 guidelines of the DGN/German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN, lead management: G. Deuschl and W. Maier) and the latest amendments of the European Federation of Neurological Societies/European Society of Neurology (EFNS-ENS, Sorbi et al. Eur J Neurol 19:1159-1179, 2012) guidelines. The forms of neurodegenerative dementia addressed are Alzheimer's disease, frontotemporal dementia and Lewy body dementia. Specific statements on the treatment of dementia in Parkinson's disease and vascular dementia can be found in separate guidelines. An analogous article on psychosocial interventions was recently published in Der Nervenarzt (Kurz, Nervenarzt 84:93-103, 2013).
引用
收藏
页码:1589 / 1600
页数:12
相关论文
共 44 条
[1]  
[Anonymous], COCHRANE DATABASE SY
[2]  
[Anonymous], COCHRANE DATABASE SY, DOI DOI 10.1002/14651858.CD001190
[3]   Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality [J].
Ballard, Clive ;
Creese, Byron ;
Corbett, Anne ;
Aarsland, Dag .
EXPERT OPINION ON DRUG SAFETY, 2011, 10 (01) :35-43
[4]  
Birks J., 2009, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD003120.pub3, DOI 10.1002/14651858.CD003120.PUB3]
[5]   Memantine in patients with frontotemporal lobar degeneration: a multicentre, randomised, double-blind, placebo-controlled trial [J].
Boxer, Adam L. ;
Knopman, David S. ;
Kaufer, Daniel I. ;
Grossman, Murray ;
Onyike, Chiadi ;
Graf-Radford, Neill ;
Mendez, Mario ;
Kerwin, Diana ;
Lerner, Alan ;
Wu, Chuang-Kuo ;
Koestler, Maly ;
Shapira, Jill ;
Sullivan, Kathryn ;
Klepac, Kristen ;
Lipowski, Kristine ;
Ullah, Jerin ;
Fields, Scott ;
Kramer, Joel H. ;
Merrilees, Jennifer ;
Neuhaus, John ;
Mesulam, M. Marsel ;
Miller, Bruce L. .
LANCET NEUROLOGY, 2013, 12 (02) :149-156
[6]   NEUROLEPTIC SENSITIVITY IN DEMENTIA WITH CORTICAL LEWY BODIES [J].
BYRNE, EJ ;
BURNS, A ;
WAITE, J .
BRITISH MEDICAL JOURNAL, 1992, 305 (6862) :1158-1159
[7]  
Devanand DP, 2013, NEW ENGL J MED, V368, P187
[8]   Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease [J].
Doody, RS ;
Dunn, JK ;
Clark, CM ;
Farlow, M ;
Foster, NL ;
Liao, T ;
Gonzales, N ;
Lai, E ;
Massman, P .
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2001, 12 (04) :295-300
[9]   Efficacy and safety of galantamine in patients with dementia with Lewy bodies: A 12-week interim analysis [J].
Edwards, KR ;
Hershey, L ;
Wray, L ;
Bednarczyk, EM ;
Lichter, D ;
Farlow, M ;
Johnson, S .
DEMENTIA AND GERIATRIC COGNITIVE DISORDERS, 2004, 17 :40-48
[10]  
Emre M, 2002, INT J CLIN PRACT, P64